- $1.10bn
- $5.11bn
- $2.46bn
Brief: Clarivate Completes Refinancing Of Term Loan, Revolver Extension
Brief: Clarivate Announces Commencement Of Term Loan Refinancing Transaction
Brief: Clarivate Reaffirms 2023 Outlook
Brief: Exor NV Reports 6.29% Stake In Clarivate PLC As Of Oct 12 - SEC Filing
Brief: Impactive Capital Lp Reports 5.3% Stake In Clarivate PLC As Of October 6 - SEC Filing
Brief: Clarivate Announces Termination Of Tax Benefits Preservation Plan
Brief: Clarivate Announces Termination Of Tax Benefits Preservation Plan
Brief: Elliott Investment Management Dissolves Share Stake In Paypal, Clarivate
Brief: Clarivate Amends Share Repurchase Program As Part Of Balanced Capital Allocation Plan
Brief: Clarivate Says FDA And Co Extend Material Transfer Agreement For Three Additional Years
Clarivate rises after Q1 results beat
Brief: Clarivate Reports First Quarter 2023 Results
Brief: Clarivate posts Q1 revenue USD 629.1 million
On March 9, Announced It Reaffirmed Its Guidance Previously Announced On March 1, 2023 For The Year Ending December 31, 2023
Brief: Clarivate Reports Fourth Quarter And Full Year 2022 Results
British biotech IPO funding dried up in 2022, report shows (updated)
Brief: Clarivate Reduces Board Size, Enhancing Corporate Governance
NYSE ORDER IMBALANCE 678316.0 SHARES ON BUY SIDE
NYSE ORDER IMBALANCE 123668.0 SHARES ON BUY SIDE